HEPS (HEPS) Stock Price & Analysis
HEPS (HEPS) rose 1.47% to USD 2.77 as of June 9, 2026 at 23:47 UTC, according to Nexqual real-time market data.
HEPS last closed at USD 2.73; the session ranged USD 2.73–2.79 on volume of 81,270 shares. Market capitalization is $989.51M, with a 52-week range of USD 2.15–3.33 (NMS). Source: Nexqual, June 9, 2026 at 23:47 UTC.
Key Statistics (as of June 9, 2026 at 23:47 UTC)
| Price | USD 2.77 |
|---|---|
| Change | ▲ 1.47% (up) |
| Previous Close | USD 2.73 |
| Open | USD 2.74 |
| Day Range | USD 2.73 – 2.79 |
| 52-Week Range | USD 2.15 – 3.33 |
| Volume | 81,270 shares |
| Market Cap | $989.51M |
| Exchange | NMS |
Technical Analysis (HEPS)
Nexqual's technical model rates HEPS "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 23:47 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.77 (neutral) |
| vs SMA50 | Above (USD 2.74) |
| MACD | -0.01 (negative) |
Analyst Ratings (HEPS)
Wall Street analysts rate HEPS "None" based on 3 analysts, with a mean price target of USD 3.27 (range USD 2.91–3.96), per Nexqual as of June 9, 2026 at 23:47 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 3.27 |
| High Target | USD 3.96 |
| Low Target | USD 2.91 |
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (HEPS)
| Next Earnings Date | 2026-07-30 |
|---|
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Financials & Fundamentals (HEPS)
| Revenue Growth (YoY) | +60.80% |
|---|---|
| Gross Margin | +25.56% |
| Operating Margin | +0.00% |
| Profit Margin | -7.00% |
| ROE | -272.77% |
| Debt / Equity | 185.74 |
| Current Ratio | 0.82 |
| Free Cash Flow | $3.37B |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Financial Health Score (HEPS)
Nexqual rates HEPS's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:47 UTC.
| Growth | Strong — Revenue +48% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 26%, operating 0% |
| Balance Sheet | Critical — Debt/Equity 1.9x |
| Cash Flow | Mixed — FCF $3.37B, slim 4.0% margin |
| Efficiency | Critical — ROE -273%, ROA -2.4% |
Ownership (HEPS)
| Insider Ownership | +65.29% |
|---|---|
| Institutional Ownership | +8.72% |
| Shares Outstanding | 317.23M |
| Float | 52.67M |
| Short % of Float | +10.40% |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Leadership (HEPS)
HEPS is led by Nilhan Gokcetekin (age 46), Chief Executive Officer, per Nexqual as of June 9, 2026 at 23:47 UTC.
| Chief Executive Officer | Nilhan Gokcetekin (age 46) |
|---|---|
| Chief Financial Officer | Mehmet Seckin Koseoglu (age 52) |
| Chief Technology Officer | Alexey Shevenkov (age 41) |
| Investor Relations Director | Ceren Tuzcu Seyhunlu |
Major Backers & Investors (HEPS)
Notable institutional backers of HEPS include Vr Advisory Services Ltd, BNP Paribas Financial Markets, UBS Group AG, according to Nexqual as of June 9, 2026 at 23:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Vr Advisory Services Ltd | 4.61% |
| BNP Paribas Financial Markets | 0.24% |
| UBS Group AG | 0.23% |
| Morgan Stanley | 0.15% |
| GAM Holding AG | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 0.89% |
| BlackRock | 0.77% |
Source: Nexqual, June 9, 2026 at 23:47 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IPW | iPower Inc. | USD 3.77 | ▲ 24.01% |
| BSFC | BLUE STAR FOODS CORP. | USD 0 | ▼ 30% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
| SGLY | Singularity Future Technology L | USD 0.36 | ▼ 5.53% |
| TIL | Instil Bio, Inc. | USD 8.02 | ▼ 0.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:47 UTC. This page is informational and not investment advice.